{"disease":{"id":"b-cell-acute-lymphoblastic-leukemia-b-all","name":"b cell acute lymphoblastic leukemia b all"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01865617","title":"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT06137118","title":"AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":163,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06364423","title":"Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06581081","title":"Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia","phase":"NA","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05480449","title":"Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":89,"lead_sponsor_name":"Stephan Grupp MD PhD","has_results":false},{"nct_id":"NCT07109219","title":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":83,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT00856388","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05397496","title":"Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT07493408","title":"Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT03595917","title":"ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Marlise Luskin, MD","has_results":false},{"nct_id":"NCT07502118","title":"NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Health Institutes of Turkey","has_results":false},{"nct_id":"NCT01384513","title":"A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT01588015","title":"Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT01567709","title":"Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05639179","title":"Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","has_results":false},{"nct_id":"NCT07205315","title":"A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Grit Biotechnology","has_results":false},{"nct_id":"NCT04746209","title":"Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT05016947","title":"Venetoclax Plus Inotuzumab for B-ALL","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":23,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06514768","title":"JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","has_results":false},{"nct_id":"NCT06785324","title":"Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT04166838","title":"The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Shanghai Longyao Biotechnology Inc., Ltd.","has_results":false},{"nct_id":"NCT01044745","title":"Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"University of Nebraska","has_results":true},{"nct_id":"NCT03579888","title":"CD19-Specific T Cells Post AlloSCT","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03878524","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT05513612","title":"Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Shanghai Pudong Hospital","has_results":false},{"nct_id":"NCT05571540","title":"Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Kunming Hope of Health Hospital","has_results":false}],"total":30},"guidelines":[],"source":"Drug Landscape verified database"}